• In September 2023, Sekur Private Data announced that it had signed a distribution agreement with VYRE Network, a leading news-based streaming channel and website, for the Sekur suite of solutions
• The company has no debt and no convertible equity
• Sekur Private Data in June 2023 announced that it is on track to launch Sekur Enterprise Solutions, its new product for SMBs, large enterprises and government organizations
• The company plans to launch SekurIdentity, its new identity theft protection solution, in 2024
• Sekur Private Data plans international business expansions in Latin America, Australia and Europe in 2024

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at www.Sekur.com, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.

Products

Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

• SekurMail(R) is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
• SekurVPN(R) creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
• SekurMessenger(R) is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (“GDSA”) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

For more information, visit the company’s website at www.SekurPrivateData.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• Lexaria’s IND application builds on five previous human clinical studies showing zero serious adverse effects and evidencing a reduction in resting blood pressure in test subjects
• DehydraTECH(TM)-CBD has the potential to have pronounced clinical benefits relative to the available anti-hypertensive therapeutics on the market today
• Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application
• Lexaria is waiting to submit until the necessary documentation outside of their control is ready for the IND application

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming Investigational New Drug (“IND”) submission. The application is for the company’s planned US Phase 1b Hypertension Clinical Trial HYPER-H23-1, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” looks to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM)-processed CBD in hypertensive patients.

Lexaria’s IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in an aggregate total of 134 healthy and hypertensive persons and evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens. The studies also showed zero serious adverse effects, evidencing Lexaria’s DehydraTECH-CBD’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” said Chris Bunka, CEO of Lexaria (https://ibn.fm/Fiizr).

Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application. However, work outside the company’s control remains delayed, including the provision of required documentation by a materials supplier and stability testing of the material. Despite this delay, Lexaria is still progressing toward its application submission.

The company is only aware of a handful of other published research investigating whether a decrease in resting blood pressure is possible following multiple weeks of oral CBD use. Lexaria notes that none of this published research has succeeded in achieving this goal. The outcomes of the company’s previous research prove DehydraTECH-CBD’s superior power to reduce blood pressure over oral CBD formulations.

Lexaria’s DehydraTECH technology is designed for formulating and delivering lipophilic drugs and active pharmaceutical ingredients (“APIs”). DehydraTECH increases their effectiveness and improves the way these APIs enter the bloodstream. The major benefits of a DehydraTECH-enabled drug or consumer product include:

• Faster delivery time – with the effects of the product felt in minutes
• Increased bioavailability – the technology is more effective at delivering a drug or product directly to the bloodstream
• Increased brain absorption – animal testing has suggested significant improvement in the quantity of the drug delivered across the blood-brain barrier
• Improved potency – more of the ingested product is made available to the body, with lower dosages necessary for the desired result
• Reduced administration costs – lower dosages mean less overall drug costs
• Masking unwanted tastes – the technology eliminates or reduces the need for sweeteners

DehydraTECH is suitable for use with various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, topicals and over-the-counter capsules, pills, tablets, and oral suspensions. The company’s technology is best considered an additional layer that can improve the effectiveness of existing drug offerings or planned new offerings. Lexaria’s DehydraTECH is covered by over 30 granted patents and has many more pending worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

DGE invites medical device design, safety, and compliance professionals to attend the 4th Human Factors Engineering & Usability Studies Congress to be held at The Bellevue Hotel, Philadelphia, PA, October 4-5, 2023. The distinguished event serves as a decisive knowledge-sharing platform focused on the complicated procedural, technical, and collaborative challenges that usability teams face.

The 4th Human Factors Engineering & Usability Studies Congress focuses on understanding and meeting FDA expectations, working with diverse user groups, recognizing the role of user fear and embarrassment, and determining just how much realistic detail is necessary for simulated use environments.

Improved User Experience and Regulatory Success

The 4th Human Factors Engineering & Usability Studies Congress aims to improve user experience and regulatory success through groundbreaking designs of medical devices, IFUs, and combination products. The event promises to delve into the importance of creating IFUs that align with user knowledge, ensuring the key information is coherent and logical.

The industry experts will share their perspectives and insights into the art of designing user interfaces that impart confidence in algorithmic device decisions. It’s an unmatched opportunity for attendees to connect with like-minded individuals and gain valuable knowledge about customizable device designs that rapidly adapt to formulation changes.

Registration for the event is now open. Interested participants should register for the 4th Human Factors Engineering & Usability Studies Congress and be a part of an innovative community driven toward medical transformation.

To learn more, please visit https://ibn.fm/0Knj7.

Investors, industry leaders, decision-makers, and business owners, are invited to attend the GSMI “EV Charging Infrastructure Summit”, September 27-28, 2023. This virtual event will explore sustainable energy solutions while driving advancement and positive change within the industry. Featuring interactive panel discussions and insightful keynote presentations, the EV Charging Infrastructure Summit offers an important platform for innovation and collaboration.

As the electric vehicle trend is gaining momentum, businesses are looking for an accessible and robust EV charging infrastructure. Serving as a beacon of technological innovation, the EV Charging Infrastructure Summit promises to pave the path for a greener and cleaner future. Attendees will get an incredible opportunity to meet industry experts and gain valuable knowledge related to the future of transportation. They will gain valuable information about the latest sustainable charging solutions.

Exploring the innovations in EV charging technology

The EV Charging Infrastructure Summit will feature some of the brightest minds in the EV charging industry. The business leaders will share insights into highly sophisticated energy management systems, charging stations, and much more. Attendees can leverage this unique opportunity to connect with potential collaborators and build valuable relationships that can help streamline EV charging projects.

The EV Charging Infrastructure Summit will showcase an exclusive blend of cutting-edge solutions and ideas that have the potential to disrupt the infrastructure, government, and reliable energy sectors. Industry pioneers will share their global perspectives on the challenges and opportunities industry. Attendees will witness the vision of EV-related start-ups and gain insights into the government initiatives and incentives that are driving sustainable electric infrastructure. Interested participants should book their spot for this one-of-a-kind event and be a part of the evolving EV charging landscape. Please don’t miss out.

To learn more, please visit https://ibn.fm/XD6C3.

• California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed
• Renovaro recently announced a binding, exclusive letter of intent (“LOI”) to add GEDI Cube’s artificial intelligence (“AI”) data mining technology to its fight against such cancers
• GEDI Cube is strengthening its platform’s potential by joining with the NVIDIA Inception program, which nurtures start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists
• The companies hope to detect pancreatic tumors at early stages when they can be more effectively treated, using predictive modeling to analyze patients’ health profiles and potential responsiveness to therapeutic efforts

Pre-clinical biotechnology innovator Renovaro BioSciences (NASDAQ: RENB) is seeking solutions for hard-to-treat cancers and other illnesses through the use of a proprietary cell and gene solution designed to promote immune system response.

The company has demonstrated the potential of its novel technology against solid tumors in humanized mouse models that demonstrated significant pancreatic tumor size and weight reduction. Renovaro has applied for Investigational New Drug (“IND”) status that would facilitate shipping the company’s experimental therapies across state lines for use in clinical trials as it focuses on potential solutions for pancreatic cancer.

Renovaro further enhanced its opportunities for developing cancer-fighting solutions recently when it announced intent to join forces with GEDI Cube Intl Ltd. — a cutting edge health company that has developed an artificial intelligence / machine learning (AI/ML) platform expected to improve the early detection of difficult cancers at a stage when treatments may be more effective. The move is expected to greatly enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches.

“Our advanced cell, gene, and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms,” Renovaro CEO Dr. Mark Dybul stated (https://ibn.fm/3XHgP). “I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”

GEDI Cube’s AI/ML platform uses a data-driven approach to detecting tumors and developing a predictive model of patients’ susceptibility to various cancers. The platform’s data is multi-omic, meaning data sets from different “omic groups” such as genomics, proteomics, transcriptomics, epigenomics, and microbiomics, are combined during analysis to develop a more thorough analysis of patients’ health conditions, since the varied omic processes influence and regulate each other (https://ibn.fm/3Nydz).

On Aug. 30, GEDI Cube announced it will be getting support for its multi-omics research from the NVIDIA Inception program, which nurtures start-ups by providing access to cutting-edge technology, technical resources and venture capitalists (https://ibn.fm/jvHP4).

NVIDIA’s infrastructure will use the Medical Imaging Open Network for Artificial Intelligence (“MONAI”) in an upcoming clinical trial designed to recognize tumors and build a predictive model based on their size and type, using GEDI Cube’s multi-omic platform in a multi-modal combination to “help provide important information for fighting cancers … that nearly always present in late stages and have predominately poor outcomes,” the news release states.

“This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage,” GEDiCube CEO Craig Rhodes stated. “(Combining) NVIDIA’s advanced medical imaging capabilities with GEDiCube’s existing multi-omic AI system will help create an algorithm that pulls from both the imaging and omic modals. This will help our scientists understand the radiology and pathology imaging data alongside multi-omic data, thus enabling a better analysis of cancer.”

For more information, visit the company’s website at www.EnochianBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

• CEO notes that prospecting, mapping and sampling have provided an extensive base of information to support drilling and IP survey
• Last month’s property-wide mapping and sampling program confirmed a structural connection between two key sections of the property
• This month’s drilling program will test the extent of the mineralization and study how the systems at Deer Horn and Pond are related

First Tellurium (CSE: FTEL) (OTCQB: FSTTF) has wrapped up a property-wide mapping and sampling program at its Deer Horn property in west-central British Columbia and is preparing to launch a drill program later this month (https://ibn.fm/1qlq6). Based on data gathered through mapping and sampling programs, drilling at Deer Horn will focus on the Pond zone copper-gold porphyry target, the company stated (https://ibn.fm/XdLOa).

“Our prospecting, mapping and sampling over the past two years have given us an extensive base of information to support the drilling and IP survey,” said Tyrone Docherty, First Tellurium president and CEO. “What we have learned is that both the copper-gold porphyry target and gold-silver-tellurium vein system extend much farther than we first understood. Even more important is the discovery last month that the two mineralized systems are connected, supporting the premise that the property could support a large copper-gold porphyry across ground that has never been explored.”

Docherty also stated the First Tellurium is launching an Induced Polarization (“IP”) geophysical survey, which will follow up on earlier rock sampling, channel sampling and prospecting.

Studies and research the company has conducted in the past several weeks have been critical as First Tellurium has planned its next steps. In August, graduate students from the University of British Columbia and the University of St. Andrews (Scotland), under the direction of First Tellurium consultant Professor Lee Groat, began conducting a property-wide mapping and sampling program (https://ibn.fm/VWqAU). The objective of the comprehensive survey was to evaluate a large portion of untested ground and provide information that could be combined with earlier mapping and sampling programs done in 2012.

Within a week, the program had produced exciting results, confirming a crucial structural connection between the property’s Pond copper porphyry and gold-silver-tellurium systems (https://ibn.fm/Z7TSL). “Mineralized veins on either side of the property are likely part of a larger ore forming process that generated both mineralized systems,” the company reported. “Preliminary results . . .  confirm that the primary structure within the Deer Horn property is a large, east-west trending thrust fault. Historically, mineral exploration has focused on the southeastern part of the property, where high grade gold-silver-tellurium (Au-Ag-Te) mineralization is predominantly located in quartz veins associated with this thrusting event.

“More recently, due to glacial recession, new sites in the northwestern part of the property have been uncovered, where significant copper mineralization has been observed at the Pond showing and adjacent areas,” the report continued. “This is thought to be part of a new porphyry copper system, potentially similar to the nearby Huckleberry Mine.”

By the end of August, the property-wide mapping and sampling program had reinforced a key porphyry alteration model and provided drill targets for this month’s drill program (https://ibn.fm/GqDNj). “The location and orientation of both the Pond and Saddle porphyry zones align with well-established porphyry alteration zone models,” observed Groat. “The alteration zones observed on surface indicate that a potassic zone lies in the subsurface at the Pond area. This is one of the key markers for a mineralized copper porphyry. All this information reinforces the premise that Deer Horn supports a copper porphyry system in an area that has never been drilled. The initial drilling in September will give us further crucial information.”

September’s drill program will consist of one drill pad in the Pond zone and two drill pads in the Saddle-New vein area. The objective of the program is to test the extent of the mineralization between the Deer Horn and Pond showings and to study how the systems at Deer Horn and Pond are related.

First Tellurium is committed to generating revenue and value by exploring responsibly and leveraging diverse partnerships. Our polymetallic (tellurium, gold, silver, copper, tungsten) Deer Horn Project in British Columbia and Klondike tellurium-gold property in Colorado anchor a diversified search for metals, working in alliance with Indigenous peoples, NGOs, governments and leading metals buyers.

For more information, visit the company’s website at www.FirstTellurium.com.

NOTE TO INVESTORS: The latest news and updates relating to FSTTF are available in the company’s newsroom at https://ibn.fm/FSTTF

• The global customer engagement solutions market is growing exponentially, driven by reduced churn rates and a preference for e-commerce platforms
• Larger companies in the industry, like Service Now, Salesforce, and OpenAI, have seen significant revenue and market caps based on their marketing offerings
• Electronic Servitor Publication Network’s Digital Engagement Engine(TM) offers a unique multi-channel digital engagement experience that allows for targeting the narrowest of niches

Valued at $19.3 billion in 2022, the global customer engagement solutions market is expected to grow at a CAGR of 10.8% through 2027, with a value of $32.2 billion. Factors contributing to this growth are reduced churn rates and the preference for e-commerce platforms (https://ibn.fm/f48Us). Larger companies in the industry have seen significant revenue and market caps due to providing clients with customer engagement solutions. Companies like Service Now ($7.2 billion revenue/$111 billion market cap), Salesforce ($31 billion revenue/$204 billion market cap), and OpenAI ($200 million revenue/$30 billion market cap) share the industry landscape with smaller companies that are making waves in the market.

One of those smaller companies is a market-disrupter and making a difference. Electronic Servitor Publication Network (OTCQB: XESP) is a digital engagement company offering a Managed Service that provides unique digital activation and engagement solutions to companies that seek to optimize their growth. The company’s Managed Service is powered by a proven, proprietary technology – the Digital Engagement Engine(TM) – which provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action and drive growth.

Traditional methods of marketing – SEO, social media marketing, content marketing, and video marketing, along with omnichannel distribution – are solutions being pushed by marketing gurus worldwide. While these methods provide benefits, companies are finding that they are not adequately addressing their needs or providing desired results.  Part of the problem is that as more and more businesses rush to use these channels, the digital engagement space is being clogged with a large volume of unfocused and static content.  In order to address the problem growth-focused companies are finding that expanding and meeting target audiences with a carefully tailored dynamic approach becomes necessary.

Electronic Servitor Publication Network’s Digital Engagement Engine(TM) was designed to drive growth for established and developing organizations and to ensure that client content is relevant, reaches target audiences, and connects with the intended person at the right time. The company calls this “Growth as a Service.”

Their Digital Engagement Engine(TM) is a laser-focused approach that makes every customer feel like they are being spoken to directly. This offering includes:

• Cutting-Edge Data Analysis – Smart tools and technologies that acquire data
• Identification Tech Stack – Capable of identifying the narrowest of niches within your target market
• Tailored Content – Creates content to meet your customers’ exact needs
• Precision Delivery – Educate and sell to customers at the right moment and time in the sales process

Implementing the Digital Engagement Engine(TM) is effortless and completely managed by the Electronic Servitor Publication Network team. This lets customers focus on their brand, product offering, and content creation. Using a risk-averse business model, the company provides an easily budgeted quarterly investment and an upside bonus that allows business growth to fund the customer’s investment.

Earlier this year, Electronic Servitor Publication Network announced a new Channel Partner program as an addition to its business strategy. The partnership includes providing its managed services and Digital Engagement Engine(TM) through its channel partners. This co-branded approach provides customers with a trusted, single point of contact from the agency while gaining the benefits of a service solely focused on driving growth. This allows agencies to drive value for their customers while de-risking the investment in new technologies and staff.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• U.S.-based generic drug developer SOHM is working to build its product pipeline through registration for distribution in several states and the planned establishment of its own product manufacturing plant in Southern California
• SOHM is also focused on developing a regenerative medicine portfolio, having issued an LOI recently in its bid to acquire the gene editing technology ABBIE from CGA Intellectual Holdings Inc.
• ABBIE is a synthetic enzyme technology that includes a DNA binding solution and a DNA integration solution for introducing a functionally edited genome into an “enhanced” cell that could then be introduced into a patient’s body to repair the effects of cellular damage
• ABBIE is still in the early stages of development, but a principal aim of SOHM’s plans for the technology is to develop cells that can help repair damaged tissues in cardiac patients’ hearts 

Generic drug manufacturing and distributing innovator SOHM (OTC: SHMN) is an innovator in regenerative medicine, nutraceuticals and cosmeceuticals through the development of cost-effective generic drugs for the breadth of major treatment categories.

The company’s drive to sustain the pharmaceutical drug supply chain has led it to pursue the acquisition of a disruptive stem cell technology known as ABBIE for editing the genes of these select cells and then using the “enhanced” cells to treat conditions such as ischemic heart disease or heart failure.

SOHM signed a letter of intent in August to potentially acquire ABBIE (A Binding Based Integrating Enzyme) from CGA Intellectual Holdings Inc. (https://ibn.fm/Mf5w3). The company’s aim is to continue studying the optimal “payload” size for delivering the edited genes to the cells of interest in testing that uses animal and human cells outside of the body (ex vivo) for eventual “plug and play” purposes in vivo.

“The donor DNA can be customized to contain any gene or combination of genes. The investigator will leverage the ABBIE targeting system and guide payloads to sites of interest to change the state of the cell,” COO Dr. David Aguilar, Ph.D., stated in an August blog entry (https://ibn.fm/ANVvl). “By using ABBIE, researchers can insert genes that can enhance the properties or functions of a desired cell type. … ABBIE can be used to insert genes that can protect stem cells from oxidative stress, inflammation, or apoptosis and thereby increase therapeutic potential. In another example, ABBIE edited cells can restore function of dysfunctional organ tissue that was affected by a genetic disorder.”

SOHM hopes to establish that edited stem cells can be used to repair a damaged heart by transplanting the stem cells or their derivatives into the heart to either regenerate or replace the damaged tissue and restore its function. 

Stem cells have long been recognized as building blocks that have the ability to transform themselves into various types of cells in the body, making them an ideal target for editing and eventual insertion into damaged organs for corrective purposes.

“ABBIE is a novel and powerful technology designed to edit the genome of cells with high precision and efficiency,” Aguilar stated. “ABBIE will soon become a reality and make a difference in the lives of millions of people who suffer from heart disease.”

SOHM’s generic pharmaceutical, nutraceutical, cosmeceutical and OTC product pipeline is in the process of expansion as the company registers for distribution in a number of states. The company intends to have more than 25 SOHM labeled products in distribution by the end of the year or by early 2024.

SOHM also continues to work toward the launch of its own manufacturing facility in San Diego, Calif.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• Silex Holdings, a subsidiary of holding company RJD Green, revealed that they would be implementing the use of software platform, StoneAPP across its business
• The software is expected to assist the company in both, reducing overall inventory costs whilst generating other ancillary savings expected to total as much as $300,000 per annum
• Silex has been a recent beneficiary of the U.S. home renovation boom, seeing its orderbook swell to record levels
• The company has simultaneously looked to introduce further operational efficiencies within its business, with StoneAPP’s implementation amongst these

Silex Holdings Inc, a Tulsa, Oklahoma-based wholesaler and distributor of kitchen building products and subsidiary of holding company, RJD Green (OTC: RJDG), recently revealed that it would be fully implementing the use of StoneAPP within its operations. The Stone Grid-designed software platform has gained renown within the stone fabrication industry for its functionality and ability to help clients streamline both, production and operational functions given its broad array of applications – ranging from project and inventory management tools through to accounting and quote management functions (https://ibn.fm/MxJlq).

Silex Holdings have stated that they expect the software to help reduce the company’s inventory costs by as much as 30 percent with ancillary cost savings from the company’s other operational activities resulting in a further 10 percent reduction to their cost base, with cumulative annual savings totaling over $300,000 per annum.

Home improvements have risen in popularity over the past few years, with the recent 2022 U.S. Houzz and Home Study (https://ibn.fm/YNcDa) revealing that American homeowners’ median renovation spend had grown by 20 percent, rising from $15,000 in 2020 to $18,000 in 2021. Kitchen renovations were featured as the most popular upgrade item, with homeowners investing 25 percent more in kitchen upgrades in 2021 relative to the previous year.

Whilst Silex has been a beneficiary of the ongoing home renovation boom – the company’s order backlog had grown to over $2,400,000 as of May 31, 2023 – a relentless focus on operational efficiency and cost controls helped Silex contribute to parent company, RJD Green’s net operating profit margin expanding to 10.5% in the most recent quarter (https://ibn.fm/XaZPH).

Ron Brewer, CEO of RJD Green Inc., commented in relation to the company’s operational focus: “Silex continues to increase its most profitable sectors, commercial projects and high-end commercial homes while maintaining their ongoing home builder and retail business. Silex Holdings is now focusing on profit enhancements such as inventory savings where the return-of-investment is recovered in year one allowing Silex to create ongoing cashflow benefits in the years following.”

A recent research report by Statista forecast that home improvement sales within the United States were expected to grow to over $620 billion dollars by 2025, rising from a value of $538 billion in 2021. Seeking to fill an underpenetrated market niche between Home Depot and local contractor companies, Silex has sought to capitalize on the industry’s growth through both, its focus on manufacturing and installing granite and other countertops, cabinets, and other products as well as its expansive customer base, ranging across residential builders, commercial contractors, and DIY customers, alike.

For more information, visit the company’s website at www.RJDGreen.com.

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

• SenesTech announced in August 2023 the closing of an exercise of warrants to purchase nearly 3 million shares of its common stock, with proceeds earmarked for existing product launches
• The company in July 2023 began delivery of the Isolate Bait System(TM), its newest delivery system for ContraPest(R)
• SenesTech reported Q2 2023 revenues of $305,000, compared to $277,000 in Q2 2022
• The company reported gross profit of $142,000 in Q2 2023, compared to $136,000 for the same period one year earlier
• In May 2023, investment firm H.C. Wainwright & Co. had a ‘Buy’ rating on SenesTech shares

SenesTech (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest(R)

SenesTech’s first product, ContraPest(R), applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest(R) targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest(R) is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest(R), the Isolate Bait System(TM). This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest(R) that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System(TM), a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System(TM), a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest(R) saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES